Apollomics, Inc. (APLM) Stock

Apollomics, Inc. (APLM) is a Healthcare stock trading at $23.38 (as of 2026-08-21), with a market capitalization of $37.46M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Apollomics, Inc. is a biotechnology company focused on discovering and developing oncology therapies, with operations in California, Hangzhou and Shanghai (China), and Australia. It develops small-molecule and tumor inhibitor candidates including APL-101 (Vebreltinib), APL-102, and APL-122.

Valuation — source: SEC EDGAR (first-party)
Price$23.38
Market Cap$37.46M
Price / Book7.70
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Return on Equity-1107.3%
Current Ratio1.39
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderKestra Advisory Services, LLC ($81884.00)
Institutional Holders Tracked7
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOHung-Wen Chen
Employees13
CountryUS
IPO Date2021-11-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Silo Pharma, Inc. (SILO)
  • Veru Inc. (VERU)
  • PDS Biotechnology Corporation (PDSB)
  • CervoMed Inc. (CRVO)
  • Actinium Pharmaceuticals, Inc. (ATNM)
  • Lite Strategy, Inc. (LITS)
  • MIRA Pharmaceuticals, Inc. (MIRA)
  • Actuate Therapeutics Inc (ACTU)
APLM earnings history · APLM institutional & insider holders · APLM KPIs & operating metrics · APLM financials · APLM investor presentations & press releases · APLM SEC filings · APLM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.